Scarica l'app Stockscreener
105.00
2.33%
2.39
Precedente Chiudi:
$102.61
Aprire:
$101.1
Volume 24 ore:
305.22K
Relative Volume:
0.61
Capitalizzazione di mercato:
$112.39M
Reddito:
$7.10M
Utile/perdita netta:
$-39.43M
Rapporto P/E:
-111.70
EPS:
-0.94
Flusso di cassa netto:
$-46.50M
1 W Prestazione:
-1.26%
1M Prestazione:
-18.94%
6M Prestazione:
-86.69%
1 anno Prestazione:
-90.34%
Intervallo 1D:
$95.97
$112.26
Intervallo di 1 settimana:
$95.97
$127.90
Portata 52W:
$7.26
$543.38
Spruce Biosciences Inc Stock (SPRB) Company Profile
Nome
Spruce Biosciences Inc
Settore
Industria
Telefono
(415) 655-4168
Indirizzo
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Confronta SPRB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
105.00 | 109.83M | 7.10M | -39.43M | -46.50M | -0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-28 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-12-11 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-12-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-03-14 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-03-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-03-14 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-14 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-14 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-21 | Iniziato | Guggenheim | Buy |
| 2021-12-17 | Iniziato | Oppenheimer | Outperform |
| 2021-12-10 | Iniziato | The Benchmark Company | Speculative Buy |
| 2021-11-16 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-19 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-11-03 | Iniziato | Cowen | Outperform |
| 2020-11-03 | Iniziato | Credit Suisse | Outperform |
| 2020-11-03 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-11-03 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Spruce Biosciences Inc Borsa (SPRB) Ultime notizie
Spruce Biosciences (SPRB) Price Target Increased by 2,045.14% to 137.19 - Nasdaq
Citizens raises Spruce Biosciences stock price target to $259 on MPS IIIB therapy - Investing.com Australia
Citizens raises Spruce Biosciences stock price target to $259 on MPS IIIB therapy By Investing.com - Investing.com South Africa
Citizens Maintains Spruce Biosciences (SPRB) Market Outperform Recommendation - Nasdaq
SPRB: Citizens Raises Price Target for Spruce Biosciences | SPRB Stock News - GuruFocus
Spruce Biosciences Reports Q3 2025 Financial Results - TipRanks
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - BioSpace
SPRB Announces Key Financing Milestones and Regulatory Achieveme - GuruFocus
Spruce Biosciences Q3 net loss narrows - MarketScreener
Spruce Biosciences Inc expected to post a loss of $13.93 a shareEarnings Preview - TradingView
Spruce Biosciences (SPRB) Expected to Announce Earnings on Monday - MarketBeat
One new option listing and two option delistings on September 5th - MSN
Small Cap Stocks To Follow TodayOctober 6th - MarketBeat
Biotech And Tech Stocks Rally On Breakthrough News And Partnerships - Finimize
Spruce Biosciences (SPRB) Price Target Decreased by 37.30% to 6.40 - MSN
[S-3] SPRUCE BIOSCIENCES, INC. Shelf Registration Statement | SPRB SEC FilingForm S-3 - Stock Titan
Spruce Biosciences, Inc. (NASDAQ:SPRB) Given Average Rating of "Hold" by Brokerages - MarketBeat
Spruce Biosciences (NASDAQ:SPRB) Upgraded to "Outperform" at Citizens Jmp - MarketBeat
Spruce Biosciences Stock Rallied 1184%Have You Assessed the Risk - Trefis
JMP Securities Upgrades Spruce Biosciences (SPRB) - Nasdaq
Cash per share of Spruce Biosciences, Inc. – NASDAQ:SPRB - TradingView
SPRB: JMP Securities Upgrades Spruce Biosciences to Market Outpe - GuruFocus
Spruce Biosciences Raised to Market Outperform From Market Perform by JMP Securities - 富途牛牛
Spruce Biosciences stock upgraded by Citizens on promising MPS IIIB therapy - Investing.com Nigeria
Spruce Biosciences Stock Dropped 16%Have You Assessed the Risk - Trefis
Spruce Biosciences (NASDAQ:SPRB) Stock Rating Lowered by Zacks Research - MarketBeat
What is Leerink Partnrs' Forecast for SPRB FY2025 Earnings? - MarketBeat
Levi & Korsinsky Reminds Spruce Biosciences Investors of the Ongoing Investigation into Potential Violations of Securities LawsSPRB - ACCESS Newswire
Spruce Biosciences Announces $50 Million Private Placement Financing - Global Legal Chronicle
Spruce Biosciences CFO vests 2,053 RSUs; owns 6,066 shares - Stock Titan
SPRB insider filing: CEO nets 3,245 shares after RSU vest - Stock Titan
The science behind the therapy that catapulted a biopharma’s stock 1,400% and counting - Healthcare Brew
Leerink Partners Maintains Spruce Biosciences (SPRB) Market Perform Recommendation - Nasdaq
Spruce Biosciences (SPRB): Analyst Raises Price Target Significa - GuruFocus
Spruce Biosciences stock price target raised to $160 from $10 at Leerink - Investing.com Philippines
Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025) - ts2.tech
Mintz Advises the Placement Agents in Spruce Biosciences, Inc.’s $50 Million Private Placement - Mintz
Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough News – Experts Weigh In - ts2.tech
Spruce Biosciences (NASDAQ:SPRB) Upgraded at Zacks Research - Defense World
SPRUCE BIOSCIENCES, INC. trading resumes - MSN
Spruce Biosciences (NASDAQ:SPRB) Rating Increased to Strong-Buy at Zacks Research - MarketBeat
SPRB director steps down; company notes no disagreement - Stock Titan
Spruce Biosciences, Inc. Announces Resignation of Bali Muralidhar as Member of Board of Directors and as Member of the Compensation Committee of the Board, Effective October 15, 2025 - MarketScreener
Spruce Biosciences Stock More Than Quadruples After Breakthrough Therapy Designation To Therapy For Rare And Fatal Genetic Disease - MSN
Head to Head Contrast: PyroGenesis Canada (NASDAQ:PYRGF) vs. Spruce Biosciences (NASDAQ:SPRB) - Defense World
What Makes Spruce Biosciences, Inc. (SPRB) a Strong Momentum Stock: Buy Now? - sharewise.com
Spruce Biosciences’ (SPRB) “Sell (D-)” Rating Reaffirmed at Weiss Ratings - Defense World
Spruce Biosciences insider filing shows 256-share buy, 1,050 held - Stock Titan
Spruce Biosciences to sell 502,181 shares at $68.00 in private placement - MSN
Spruce Biosciences' (SPRB) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Spruce Biosciences (NASDAQ:SPRB) Shares Down 1%What's Next? - MarketBeat
Spruce Biosciences Inc Azioni (SPRB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):